Enzyme kinetics and binding studies on inhibitors of MEK protein kinase.
Inhibition of the protein kinase, MEK1, is a potential approach for the treatment of cancer. Inhibitors may act by prevention of activation (PoA), which involves interfering with phosphorylation of nonactivated MEK1 by the upstream kinase, B-RAF. Modulation also may occur by inhibition of catalysis (IoC) during phosphorylation of the downstream substrate, ERK2, by activated MEK1. Here, five MEK inhibitors are characterized in terms of binding affinity, PoA, and IoC. The compounds are a butadiene (U-0126), an N-alkoxy amide (CI-1040), two CI-1040 analogues (an anthranilic acid and an N-alkyl amide), and a cyanoquinoline. Some compounds give different mechanisms of inhibition (ATP-competitive, noncompetitive, or uncompetitive) in PoA compared to IoC or show a change in potency between the assays. The inhibitors also exhibit different shifts in potency when either PoA or IoC is compared with binding to nonactivated MEK. The inhibitor potency ranking, therefore, is dependent upon the assay format. When the ATP concentration equals K m, IoC IC 50 increases in the order CI-1040 approximately cyanoquinoline < anthranilic acid approximately U-0126 < alkyl amide. Conversely, the K d from nonactivated MEK1 for four of the compounds varies between more than 6-fold lower and over 18-fold higher than this IC 50, with U-0126 having the lowest K d and CI-1040 having the highest. In PoA when the ATP concentration equals K m, U-0126 has the lowest IC 50, becoming more potent than CI-1040, the cyanoquinoline, and the anthranilic acid. These observations have implications for understanding structure-activity relationships of MEK inhibitors and illustrate how assays can be designed to favor different compounds.
VanScyoc
Wendy S
WS
AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
Holdgate
Geoffrey A
GA
Sullivan
Jane E
JE
Ward
Walter H J
WH
D000255:Adenosine Triphosphate / Q000378:metabolism; D001549:Benzamides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D002070:Butadienes / Q000378:metabolism / Q000494:pharmacology; D002384:Catalysis / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000378:metabolism* / Q000494:pharmacology*; D020128:Inhibitory Concentration 50; D007700:Kinetics; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D009570:Nitriles / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D011804:Quinolines / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D013816:Thermodynamics
C120227:2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; D001549:Benzamides; D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; D011804:Quinolines; C113580:U 0126; D000255:Adenosine Triphosphate; C037219:quinoline; D048369:MAP Kinase Kinase 1